BDX logo

Becton, Dickinson and Company Stock Price

NYSE:BDX Community·US$55.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author

BDX Share Price Performance

US$193.61
-43.85 (-18.47%)
6.9% undervalued intrinsic discount
US$208.00
Fair Value
US$193.61
-43.85 (-18.47%)
7.5% undervalued intrinsic discount
US$209.37
Fair Value
Price US$193.61
AnalystConsensusTarget US$209.37

BDX Community Narratives

AnalystConsensusTarget·Updated
Fair Value US$208 6.9% undervalued intrinsic discount

Advanced Diagnostics And Tissue Regeneration Will Expand Decentralized Healthcare

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative

Recent BDX News & Updates

Becton, Dickinson: Great Time To Buy This Dividend Aristocrat

Aug 18

Becton, Dickinson and Company Key Details

US$21.4b

Revenue

US$11.3b

Cost of Revenue

US$10.1b

Gross Profit

US$8.5b

Other Expenses

US$1.6b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
5.53
Gross Margin
47.16%
Net Profit Margin
7.41%
Debt/Equity Ratio
75.9%

Becton, Dickinson and Company Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Established dividend payer with mediocre balance sheet.

2 Risks
4 Rewards

About BDX

Founded
1897
Employees
74000
CEO
Thomas Polen
WebsiteView website
www.bd.com

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 8.5%
  • 1 Year: 17.7%
  • Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. In the last year, the market has climbed 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›